Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Loratadin

Classification: B

Drug products: Allergityn, Clarityn, Clarityn®, Clarityn®-S, Loratadin ABECE, Loratadin Actavis, Loratadin Apofri, Loratadin BMM Pharma, Loratadin HEXAL, Loratadin Mylan, Loratadin Orifarm, Loratadin ratiopharm, Loratadin Sandoz, Loratadin STADA®, Versal®

ATC code: R06AX13

Substances: loratadine

Summary

Controlled studies on sex differences in efficacy and safety of loratadine are lacking.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics of loratadine has been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of loratadine has been found.

Adverse effects

An observational study based on data from General Practice Research Database in the UK (in total 197 425 persons) investigated the incidence of ventricular arrhythmias associated with use of non-sedating antihistamines (acrivastine, astemizole, cetirizine, loratadine and terfenadine). Ventricular arrhythmias were four times more common in those using non-sedating antihistamines compared to those with no use. The relative risk in women compared to men was 1.1 (95% CI 0.4-2.9) [1].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2018-12-19

Date of litterature search: 2018-12-14

References

  1. de Abajo FJ, Rodríguez LA. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol. 1999;47(3):307-13. PubMed
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-06.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson